Publications by authors named "R Salpini"
Objectives: To unravel the still unexplored HBV-replicative kinetics in anti-HBc-positive/HBsAg-negative people-with-HIV (PWH) suspending tenofovir disoproxil-fumarate/tenofovir-alafenamide (TDF/TAF).
Methods: A total of 101 anti-HBc-positive/HBsAg-negative PWH switching to TDF/TAF-sparing therapy were included. Serum HBV-DNA and HBV-RNA were quantified by droplet-digital-PCR at switching (T0), within 12 months (T1) and 12-24 months postswitch (T2).
Article Synopsis
- * Combination antiretroviral therapy (cART) is commonly used to combat HIV by blocking multiple replication stages of the virus, but it leads to drug resistance and the formation of latent HIV reservoirs.
- * Current research focuses on developing new antiviral drugs, vaccines, and updated cART strategies while examining the roles of macrophages and cellular reservoirs in HIV persistence and treatment effectiveness.
Background And Aims: HBV and HIV coinfection is a common occurrence globally, with significant morbidity and mortality. Both viruses lead to immune dysregulation including changes in natural killer (NK) cells, a key component of antiviral defense and a promising target for HBV cure strategies. Here we used high-throughput single-cell analysis to explore the immune cell landscape in people with HBV mono-infection and HIV/HBV coinfection, on antiviral therapy, with emphasis on identifying the distinctive characteristics of NK cell subsets that can be therapeutically harnessed.
View Article and Find Full Text PDFArticle Synopsis
- Equine hepacivirus (EqHV) is an RNA virus linked to mild hepatitis in horses and is present worldwide, but Italy lacks comprehensive data on its prevalence.
- A study involving 1,801 horse serum samples across various categories and regions in Italy found a national prevalence of 4.27%, with no significant differences among categories or regions.
- The research identified three known EqHV subtypes in Italy and suggested a potential fourth subtype, highlighting the need for EqHV to be included in hepatitis diagnostic protocols and blood product safety measures.